Highlights
- Unaudited FY26 Revenue was $3.9 million, down 51.1% from $8.1 million, with an underlying EBITDA loss of $6.5 million.
- The net loss was $12.4 million versus $11.0 million in FY25, while administrative expenses fell 8.9% to $4.1 million.
- It signed its first Master License Agreement with Amalgamated Vision in North America and completed a roughly $2.5 million placement.
- FY27 priorities include Cogenic delivery contracts, custom MEMS Supply and Bambach order book rebuilding expected to flow through in 3QFY27.
Energy Technologies (ASX:EGY) presented its unaudited results for the year ended 30 June 2026 in an investor presentation lodged in late August 2026, reporting lower revenue and a larger loss. At $0.026, shares were up 8.33% on 16 November, with the day's trading confined to $0.026, giving a Market Capitalisation of $16.24 million and a one-year gain of 18.18%.
Unaudited FY26 Results
Revenue was $3.9 million, down $4.2 million, or 51.1%, from $8.1 million in FY25. The underlying gross loss was $2.3 million, compared with $1.5 million, and the underlying EBITDA loss was $6.5 million, compared with $6.3 million.
The net loss was $12.4 million, compared with $11.0 million, and the presentation cited higher financing costs as a factor. Administrative expenses fell $0.4 million, or 8.9%, to $4.1 million. Cash and Debt balances were not stated in the material reviewed.
Calculated from the stated figures, the underlying EBITDA loss was about 167% of revenue in FY26, compared with about 78% in FY25, and the underlying gross loss widened by $0.8 million as revenue fell.
Licence Agreement and Placement
The company signed its first Master License Agreement, with Amalgamated Vision for North America. No value was stated.
A Placement of approximately $2.5 million was completed. The presentation said funding would be managed to extinguish debt and to fund Working Capital for Bambach.
The licence agreement is described as the company's first Master License Agreement, but the presentation did not disclose licence fees, minimum volumes or the term.
FY27 Priorities
The stated priorities are moving Cogenic to commercial delivery contracts, finalising custom MEMS supply for Volume manufacture and rebuilding the Bambach order book to prior levels, with results expected to flow through in the third quarter of FY27. The company also aims to maintain cost discipline.
No numerical guidance was given. Market sizing shown in the presentation was labelled illustrative rather than a forecast, so it should not be read as an expectation of revenue.
Company Snapshot, Sector Context and Risks to Watch
The results are unaudited management accounts and may change when the audit is completed. Revenue fell by more than half while the loss widened, so the order book rebuild and licensing progress are the key matters to follow.
Risks include reliance on further funding, delays in converting licences and supply arrangements into revenue and the absence of disclosed order book values. This article is general information only and not financial advice.
Investors can compare these unaudited figures with the audited accounts when they are released, as changes are possible.






Please wait processing your request...